Walvax BioTech vs Jiangsu Hengrui Pharma Co: Fair Value & Quality
Both stocks run through our valuation models. Here is how Walvax BioTech (300142) and Jiangsu Hengrui Pharma Co (1276) compare, as of Aug 22, 2026.
As of Aug 22, 2026, Fair Value Calculator sees Jiangsu Hengrui Pharma Co as the less overvalued of the two: Walvax BioTech trades at ¥16.10 versus a fair value of ¥1.89 (-88%), while Jiangsu Hengrui Pharma Co trades at HK$48.20 versus HK$33.59 (-30%).
Walvax BioTech
300142.SHE · CNY · Health Care
-88%
upside to fair value
overvalued
Price¥16.10
Fair Value¥1.89
Quality58/100
Jiangsu Hengrui Pharma Co
1276.HK · HKD · Health Care
-30%
upside to fair value
overvalued
PriceHK$48.20
Fair ValueHK$33.59
Quality67/100
Get comparisons like this free by email every month: the most undervalued quality stocks.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Walvax BioTechJiangsu Hengrui Pharma Co
Valuation
89.4×P/E (TTM)41.0×
8.09×P/S (TTM)11.79×
2.25×P/B5.63×
29.2×EV/EBITDA35.8×
1.0%Dividend yield0.4%
¥0.16Dividend per shareHK$0.20
Profitability
12%Net margin25%
34%Operating margin32%
3%Return on equity15%
1%Return on assets9%
Growth
-4%Revenue growth (YoY)13%
-22.0%Avg. growth/yr (3Y)13.2%
-3.9%Avg. growth/yr (5Y)2.6%
Balance & size
0.02×Debt / equity—
$3BMarket cap$49B
weakGrowth qualityhealthy
Jiangsu Hengrui Pharma Co leads: 5 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Walvax BioTechof which business quality 57 · market factors 62Jiangsu Hengrui Pharma Coof which business quality 68 · market factors 26
ProfitabilityMargins and returns on capital today
23
63
Quality GrowthAre margins and returns improving?
42
46
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
67
28
Low VolatilityCalm price path (market factor)
63
70
MomentumPrice trend over the last 3–12 months (market factor)
52
11
52W MomentumDistance to the 52-week high (market factor)
78
0
Net IssuanceBuybacks instead of dilution
82
63
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Walvax BioTech
DCF Models¥2.21
Earnings-Based¥1.82
Dividend Discount¥0.32
Multiples¥1.89
Asset-Based¥3.61
Economic Profit¥2.28
Growth Earnings¥2.72
17 of 17 models see the stock below the current price.
Jiangsu Hengrui Pharma Co
DCF ModelsHK$40.78
Earnings-BasedHK$21.65
MultiplesHK$26.01
Asset-BasedHK$6.99
Growth DCFHK$40.93
Economic ProfitHK$20.41
Growth EarningsHK$30.97
22 of 24 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Walvax BioTech
Bear ¥1.42Fair Value ¥1.89Bull ¥2.37
¥16.10 = current price (white tick)
Jiangsu Hengrui Pharma Co
Bear HK$25.19Fair Value HK$33.59Bull HK$41.04
HK$48.20 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Walvax BioTech · Health Care
Quality score58 · above median
Fair value upside-88% · bottom 25%
Jiangsu Hengrui Pharma Co · Health Care
Quality score67 · Top 25%
Fair value upside-30% · below median
Bottom line
As of Aug 22, 2026, Fair Value Calculator sees Jiangsu Hengrui Pharma Co as the less overvalued of the two: Walvax BioTech trades at ¥16.10 versus a fair value of ¥1.89 (-88%), while Jiangsu Hengrui Pharma Co trades at HK$48.20 versus HK$33.59 (-30%).
Jiangsu Hengrui Pharma Co has the higher quality score (67/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.
